Search Results

team in Oxford, buying out a fledgling biotech for $255M+ Domain Therapeutics announces first patient dosed

Learn to tie your program's progress directly to your funding runway, incorporating crucial early commercial

of adjustability in terms of pharmacological effects, allowing for the administration of substantial doses

Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,

. 👉 Biotech founders often delay critical business moves, hiring, BD outreach, or funding decisions,

patients with WHIM syndrome Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung

disorder GPCRs in Oncology and Immunology Regulator of G protein signaling protein 6 alleviates acute lung

Informatics Head or Team Lead (depending on experience) with Structural Bioinformatics Expertise Fully Funded

Months of 2023 InterAx Biotech Announces Being the Recipient of a Highly Competitive European Grant to Fund

DRD1 is exempt from TGFβ-mediated antifibrotic GPCR landscape tampering in lung fibroblasts. βHB inhibits

Transforming Growth Factor β-Mediated Antifibrotic G Protein-Coupled Receptor Landscape Tampering in Lung

prefrontal cortex cells and circuits GPCRs in Oncology and Immunology RGS20 promotes non-small cell lung

$4.6 Million in Milestone Payments from Centessa Pharmaceuticals CB1 receptor inverse agonist improves lung

Photopharmacology GPCRs in Cardiology, Endocrinology, and Taste Rap1A Modulates Store-Operated Calcium Entry in the Lung

Science evolves in parallel with regulatory funding pressure and team growth.   Without it, even strong science slowly loses direction. 👉 Understanding why biotech startups fail  is

Fibrosis Former execs from Pfizer obesity drug program have started a new biotech with $52M from VC fund

The scientific ambition may be impressive, yet the strategic narrative loses sharpness. A startup is not a fund.

Why biotech founders lose financial control without seeing it coming, and what has to be in place early For Biotech Founders, the real danger is not running out of money, but losing financial control early This is where many biotech founders lose visibility. The moment biotech founders lose flexibility is long before the bank account becomes the problem. Decisions get postponed in the hope that the next data readout, the next partnership, or the next funding

Don’t be surprised if you find yourself singing Daddy Yankee’s “Gasolina” from the top of your lungs

and Intermediate States of Orexin 2 Receptor Signaling Industry News Addex Gets Creative To Secure Funding

sulfated mCCR2 peptides can outcompete available chemokines, decreasing retinal degradation in mice (Jung

Live-cell Imaging of Bioactive Peptides Cascaded amplifying circuit enables sensitive detection of fungal

Signaling Components of TOR and MAP kinase signaling control chemotropism and pathogenicity in the fungal